Sofosbuvir plus ledipasvir for recurrent hepatitis C in liver transplant recipients
Ibrahim Hamad Altraif – 19 January 2017
Splenectomy is not indicated in living donor liver transplantation
Antonios Athanasiou, Demetrios Moris, Christos Damaskos, Eleftherios Spartalis – 19 January 2017
Reply
Kyoji Ito, Nobuhisa Akamatsu, Norihiro Kokudo – 19 January 2017
Role of microRNA in acute cellular rejection
Anand V. Kulkarni, Shiv K. Sarin, Ashok Choudhury, S.M. Shashthry, Karan Kumar, Lovkesh Anand – 19 January 2017
Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic
Iliana Doycheva, Kymberly D. Watt, Naim Alkhouri – 19 January 2017 – Nonalcoholic fatty liver disease (NAFLD) is a significant health burden in adolescents and young adults (AYAs) which has substantially risen in prevalence over the last decades. The occurrence of NAFLD parallels high rates of obesity and metabolic syndrome in this age group, with unhealthy lifestyle also playing an independent role. Genetic factors, sex, and ethnicity should be considered in a risk stratification model.
Presence of small pancreatic cystic lesions should not preclude liver transplantation
Jodie A. Barkin, Jamie S. Barkin – 19 January 2017
What is the benefit of early follow‐up after hospitalization for patients with cirrhosis?
Robert Driver, Ian A. Rowe – 18 January 2017
Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review
Veeral H. Ajmera, Norah A. Terrault, Stephen A. Harrison – 18 January 2017 – Moderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet the effects on cardiovascular and liver health are unclear. Moderate alcohol use is associated with improved insulin sensitivity and decreased cardiovascular mortality in the general population, but whether similar benefits would be observed in persons with NAFLD remains largely unstudied.
A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis
Càndid Villanueva, Isabel Graupera, Carles Aracil, Edilmar Alvarado, Josep Miñana, Ángela Puente, Virginia Hernandez‐Gea, Alba Ardevol, Oana Pavel, Alan Colomo, Mar Concepción, María Poca, Xavier Torras, Josep M. Reñe, Carlos Guarner – 18 January 2017 – Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifies the risk of variceal rebleeding (VRB). We assessed whether guiding therapy with hepatic venous pressure gradient (HVPG) monitoring may improve survival by preventing VRB.
The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis
Zongwen Shuai, Jinjun Wang, Madhu Badamagunta, Jinjung Choi, Guoxiang Yang, Weici Zhang, Thomas P. Kenny, Kathryn Guggenheim, Mark J. Kurth, Aftab A. Ansari, John Voss, Ross L. Coppel, Pietro Invernizzi, Patrick S.C. Leung, M. Eric Gershwin – 18 January 2017 – The identification of environmental factors that lead to loss of tolerance has been coined the holy grail of autoimmunity.